rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations.
|
18402691 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.
|
19639206 |
2009 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two out of the four p53(wt) relapsing breast cancer patients showed the Arg72Pro allelic variant; one of these died at 75 months.
|
12702523 |
2003 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results of present study indicated that among the five TP53 polymorphisms investigated, the p.R72P polymorphism, and the RP-A1A1 and RP-GG genotype combination contribute to breast cancer susceptibility in North Indians.
|
25169539 |
2014 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.
|
17696741 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro and PIN3(16bp duplication) polymorphisms are proposed to have an effective role in structural changes of p53 and have therefore attracted interest as a risk factor for breast cancer in different populations.
|
25854391 |
2015 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results indicated a statistically significant association (p<0.05) between rs1219648, but not rs1042522, and risk of breast cancer.
|
25292094 |
2014 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer</span> risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups.
|
22729912 |
2012 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of the rs1042522 polymorphism of TP53 was significantly higher in all groups of patients with breast cancer compared with the control group.
|
27644661 |
2016 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together, we showed the preferential loss of the rs1042522 C allele, which is protective against BC progression, in breast tumors.
|
21810023 |
2011 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The purpose of this study was to evaluate the role of Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as genetic susceptibility and predictive markers to breast cancer.
|
18230179 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.
|
20380571 |
2010 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
|
20638924 |
2010 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian population.
|
31721533 |
2020 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
|
21706156 |
2012 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For the Ex4 + 19 C > G SNP (rs1042522), women with the heterozygous genotype (G/C) had a 32% increase in breast cancer risk.
|
17624591 |
2008 |
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.
|
19639206 |
2009 |
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |